WednesdaySep 27, 2017 1:34 pm

AppSwarm, Inc. (SWRM) Continues to Support the Games People Play as a Business Accelerator

At least 150 million Americans play games Business accelerator for mobile app developers Footprint in the mammoth video games market With the latest Entertainment Software Association (ESA) report revealing that half of America plays video games, the excitement surrounding AppSwarm, Inc.’s (OTC: SWRM) foray into the industry appears to be based on very robust rationales. AppSwarm is a business accelerator focused on acquiring software applications for all forms of devices. The company actively pursues partnerships with software development companies that exhibit historical profitability and growth capability. Leveraging its resources in capital, management, marketing and product development, AppSwarm is able to…

Continue Reading

WednesdaySep 27, 2017 1:30 pm

ITUS Corp. (NASDAQ: ITUS) Starts Presentation at the 2017 Disruptive Growth Company Showcase

ITUS (NASDAQ: ITUS) is a cancer-focused biotechnology company that funds, develops, acquires and licenses emerging technologies. The company, through its subsidiary, Anixa Diagnostics Corporation, is developing a platform called Cchek™, a series of non-invasive, blood tests for the early detection of solid tumor based cancers. ITUS also frequently examines emergent technologies in related fields for further development and commercialization. For more information, visit the company’s website at www.ITUScorp.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social…

Continue Reading

WednesdaySep 27, 2017 1:30 pm

Cancer Genetics, Inc. (NASDAQ: CGIX) Starts Presentation at the 2017 Disruptive Growth Company Showcase

Cancer Genetics (NASDAQ: CGIX) develops, commercializes and provides molecular and biomarker-based tests and services in the United States, India and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company’s clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. For more information, visit the company’s…

Continue Reading

WednesdaySep 27, 2017 1:13 pm

Grey Cloak Tech Inc. (GRCK) Signs Letter of Intent to Acquire Eqova Life Sciences

Clinical-grade full spectrum hemp oil products created for licensed medical practitioners included Science-backed education, superior products meet requirements of medical profession Medical cannabinoid product revenue projected to reach $1.15 billion by 2020 Grey Cloak Tech Inc. (OTC: GRCK) recently announced that it has signed a binding Letter of Intent to purchase Eqova Life Sciences, a Colorado-based medically-focused company producing clinical-grade full spectrum hemp oil products. To date, no other hemp oil company has exclusively focused on the medical practitioner market, leaving this important segment largely underserved. Grey Cloak Tech, which is known for its click fraud prevention products, has been…

Continue Reading

WednesdaySep 27, 2017 1:00 pm

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) Starts Presentation at the 2017 Disruptive Growth Company Showcase

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. The company utilizes its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology as well as other drug delivery technologies to develop and commercialize new applications of proven therapies aimed at addressing important unmet medical needs. The company also works in partnership with third parties to develop and commercialize these products. Current marketed products and products in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain and opioid dependence. BDSI's headquarters is in Raleigh, North Carolina.…

Continue Reading

WednesdaySep 27, 2017 1:00 pm

Newater Technology, Inc. (NASDAQ: NEWA) Starts Presentation at the 2017 Disruptive Growth Company Showcase

Newater Technology (NASDAQ: NEWA) was founded in 2012 and is headquartered in Yantai, Shandong Province. Newater is a China-based wastewater purification treatment company focused on the development, manufacture and sale of disk tube reverse osmosis and disk tube nanofiltration membrane filtration products that are used in the treatment, recycling and discharge of wastewater. The company's products can be used across a wide spectrum of industries, including: leachate from landfills, waste water from oil fields, high acid waste water, power plant waste water, waste water from gas production, and desalination. The company also supplies hardware and engineered systems necessary to implement…

Continue Reading

WednesdaySep 27, 2017 1:00 pm

Zomedica Pharmaceuticals Corp. (ZOMHF) Starts Presentation at the 2017 Disruptive Growth Company Showcase

Zomedica Pharmaceuticals (OTC: ZOMHF) is a veterinary pharmaceutical and health care solutions company creating innovative products for companion animals (canine, feline and equine) by focusing on your needs as a clinical veterinarian. The company is developing a diversified portfolio to include diagnostics, devices, innovative drugs, and drug-delivery technologies. Zomedica’s team is comprised of clinical veterinary professionals with a mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit the company’s website at www.zomedica.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1)…

Continue Reading

WednesdaySep 27, 2017 11:30 am

Rexahn Pharmaceuticals, Inc. (NYSE: RNN) Starts Presentation at the 2017 Disruptive Growth Company Showcase

Rexahn Pharmaceuticals (NYSE: RNN) is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for the treatment of cancer. Rexahn's product candidates target and neutralize specific proteins believed to be involved in the complex biological force that leads to cancer cell growth. The company’s broad oncology pipeline includes three anti-cancer compounds currently in phase II clinical development: Supinoxin™, RX-3117, and Archexin®. Rexahn also has a novel nanopolymer-based drug delivery platform technology that may increase the bio-availability of FDA-approved chemotherapies. For more information, visit the company’s website at www.rexahn.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access…

Continue Reading

WednesdaySep 27, 2017 11:30 am

Yangtze River Development Limited (NASDAQ: YERR) Starts Presentation at the 2017 Disruptive Growth Company Showcase

Yangtze River Development (NASDAQ: YERR) is primarily engaged in real estate development with a port logistic project located in the middle reaches of the Yangtze River. Wuhan Newport is a large infrastructure development project implemented under China's latest "One Belt One Road" initiative and is strategically positioned in the "Free Trade Zone" of the Wuhan Port, a crucial trading window between China, the Middle East and Europe. Upon project completion, the logistics center will house six operating zones, including port operation area, warehouse and distribution area, cold chain logistics area, rail cargo loading area, exhibition area and residential community. It…

Continue Reading

WednesdaySep 27, 2017 11:00 am

PURE Bioscience, Inc. (PURE) Starts Presentation at the 2017 Disruptive Growth Company Showcase

PURE Bioscience (OTCQB: PURE) develops and commercializes proprietary antimicrobial products primarily in the food safety arena and provides solutions to pathogen and hygienic control. The company’s technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. For more information, visit the company’s website at www.purebio.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information…

Continue Reading

Contact us: 212.418.1217